Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Fate Therapeutics Inc (NASDAQ: FATE) closed at $0.92 in the last session, down -12.80% from day before closing price of $1.06. In other words, the price has decreased by -$12.80 from its previous closing price. On the day, 4.17 million shares were traded.
Ratios:
We take a closer look at FATE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.24.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.77 while its Price-to-Book (P/B) ratio in mrq is 0.33.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $5.95, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -13.50%, while the 200-Day Moving Average is calculated to be -62.95%.
Shares Statistics:
A total of 113.93M shares are outstanding, with a floating share count of 103.49M. Insiders hold about 9.70% of the company’s shares, while institutions hold 84.91% stake in the company.
